Cancer Tumor Profiling Market
完整報告名稱與涵蓋範圍
Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type (Tissue, Blood, Bone Marrow), Application, Cancer Type, End User & Region – Global Forecast to 2031
報告摘要
The cancer tumor profiling market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in 2026, at a CAGR of 10.6%. The global cancer tumor profiling market is projected to witness strong growth during the forecast period, supported by rising cancer incidence, increasing approvals of targeted therapies and immunotherapies, and growing integration of molecular profiling into routine oncology care. Market expansion is further supported by advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), liquid biopsy, and bioinformatics, along with increasing demand for comprehensive tumor characterization, treatment selection, treatment-response monitoring, recurrence detection, and biomarker-driven clinical trials. However, high assay-development and validation costs, complex regulatory pathways, reimbursement limitations, data-interpretation complexity, and uneven availability of advanced molecular testing infrastructure across regions are expected to restrain market growth to some extent.
“Assays, kits, reagents, and consumables accounted for the largest share of the cancer tumor profiling market, by offering, in 2025.”
Based on offering, the cancer tumor profiling market is segmented into products and services. Products include instruments and systems; and assays, kits, reagents, and consumables. Services include clinical tumor profiling testing services and biopharmaceutical, clinical-trial, and companion diagnostic services. In 2025, assays, kits, reagents, and consumables accounted for the largest share due to their recurring use across tissue and blood-based profiling workflows. Sequencing reagents, PCR consumables, antibodies, probes, sample-preparation kits, and other assay components are required for each patient test, creating sustained pull-through revenue. Their compatibility with high-throughput platforms and expanding use in diagnosis, molecular characterization, treatment selection, and clinical research further support the leading position of this segment.
“Next-generation sequencing accounted for the largest share of the cancer tumor profiling market, by technology, in 2025.”
Based on technology, the global cancer tumor profiling market is segmented into next-generation sequencing; polymerase chain reaction, including qPCR, RT-PCR, and digital PCR; immunohistochemistry; in situ hybridization, including FISH, CISH, and SISH; and other tumor profiling technologies. In 2025, next-generation sequencing accounted for the largest share because of its ability to analyze multiple genes and genomic alterations simultaneously, detect rare and co-occurring biomarkers, and support comprehensive genomic profiling from tissue and blood samples. Increasing use of broad oncology panels, companion diagnostic assays, and liquid-biopsy workflows, together with growing demand for scalable molecular profiling in clinical trials, is expected to reinforce the segment’s leading position during the forecast period.
“The Asia Pacific region is projected to grow at the highest CAGR in the cancer tumor profiling market from 2026 to 2031.”
The cancer tumor profiling market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is projected to register the highest CAGR due to rising cancer incidence, expanding oncology infrastructure, increasing investment in molecular diagnostics, and growing adoption of precision-medicine approaches. Growth is further supported by improving access to NGS and liquid-biopsy testing, expansion of pharmaceutical clinical trials, establishment of regional genomic laboratories, and the increasing presence of global and domestic diagnostics companies across China, Japan, India, South Korea, Australia, and Southeast Asia.
List of Companies Profiled in the Report
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Guardant Health, Inc.
• Tempus AI, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Laboratory Corporation of America Holdings (Labcorp)
• Abbott Laboratories
• Natera, Inc.
• NeoGenomics, Inc.
• Myriad Genetics, Inc.
• Agilent Technologies, Inc.
• Quest Diagnostics Incorporated
• Caris Life Sciences, Inc.
• Danaher Corporation
Research Coverage
This research report categorizes the cancer tumor profiling market by offering, technology, sample type, application, cancer type, end user, and region. The report provides detailed information on major market factors, including drivers, restraints, opportunities, and challenges. It analyzes leading industry participants and provides insights into their business overviews, product and service portfolios, technology capabilities, market positions, and key strategies, including product launches and approvals, partnerships, collaborations, agreements, acquisitions, expansions, and other recent developments. The report also covers regulatory trends, reimbursement considerations, precision-oncology adoption, biomarker-testing practices, and emerging technologies such as liquid biopsy, minimal residual disease testing, AI-enabled interpretation, spatial biology, and multi-omics. In addition, it evaluates established companies and emerging participants across the global cancer tumor profiling ecosystem.
Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing close approximations of revenue for the overall cancer tumor profiling market and its subsegments. It will help stakeholders understand the competitive landscape, identify high-growth opportunities, assess technology and regional trends, and formulate effective product, partnership, investment, and go-to-market strategies. The report also provides an integrated view of the market pulse, covering key drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
• Analysis of key drivers, including increasing adoption of precision oncology and targeted therapies, expansion of NGS-based comprehensive genomic profiling, rising use of liquid biopsy, growing cancer incidence, and increasing pharmaceutical-diagnostic collaborations. The report also examines restraints such as high development and validation costs, reimbursement limitations, and data-interpretation complexity, as well as challenges related to regulatory requirements, standardization, and limited testing infrastructure in emerging markets.
• Product Development/Innovation: Detailed insights into newly launched and pipeline tumor profiling assays, sequencing platforms, pathology solutions, liquid-biopsy tests, companion diagnostics, minimal residual disease solutions, AI-enabled interpretation tools, and integrated molecular testing workflows.
• Market Development: Comprehensive information on attractive markets and growth opportunities across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, including country-level adoption patterns and regional expansion strategies.
• Market Diversification: Exhaustive information on product and service portfolios, technology developments, regulatory approvals, pharmaceutical partnerships, clinical-trial collaborations, acquisitions, laboratory expansions, and investments in the cancer tumor profiling market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, clinical testing footprints, and service offerings of leading players, including F. Hoffmann-La Roche AG, Guardant Health, Inc., Illumina, Inc., Tempus AI, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Laboratory Corporation of America Holdings, Natera, Inc., NeoGenomics, Inc., Myriad Genetics, Inc., Agilent Technologies, Inc., Quest Diagnostics Incorporated, Caris Life Sciences, Inc., Abbott Laboratories, and Danaher Corporation.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.3 STUDY SCOPE 50
1.3.1 MARKETS COVERED & REGIONAL SCOPE 50
1.3.2 INCLUSIONS & EXCLUSIONS 51
1.3.3 YEARS CONSIDERED 52
1.4 CURRENCY CONSIDERED 52
1.5 STAKEHOLDERS 52
1.6 SUMMARY OF CHANGES 53
2 EXECUTIVE SUMMARY 54
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 54
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 55
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 56
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 57
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 58
3 PREMIUM INSIGHTS 59
3.1 CANCER/TUMOR PROFILING MARKET OVERVIEW 59
3.2 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING,
2026 VS. 2031 59
3.3 CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2026 VS. 2031 60
3.4 CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2026 VS. 2031 60
3.5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2026 VS. 2031 61
3.6 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2026 VS. 2031 61
3.7 CANCER/TUMOR PROFILING MARKET, BY APPLICATION TYPE, 2026 VS. 2031 62
3.8 CANCER/TUMOR PROFILING MARKET, BY CLINICAL APPLICATION TYPE, 2026 VS. 2031 62
3.9 CANCER/TUMOR PROFILING MARKET, BY RESEARCH AND DRUG DEVELOPMENT APPLICATION, 2026 VS. 2031 63
3.10 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2026 VS. 2031 63
3.11 CANCER/TUMOR PROFILING MARKET, BY SOLID TUMOR TYPE, 2026 VS. 2031 64
3.12 CANCER/TUMOR PROFILING MARKET, BY LIQUID TUMOR, 2026 VS. 2031 64
3.13 CANCER/TUMOR PROFILING MARKET, BY END USER, 2026 VS. 2031 65
3.14 CANCER/TUMOR PROFILING MARKET, BY HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS, 2026 VS. 2031 65
3.15 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
4 MARKET OVERVIEW 67
4.1 INTRODUCTION 67
4.2 MARKET DYNAMICS 68
4.2.1 DRIVERS 68
4.2.1.1 Increasing adoption of precision oncology and targeted therapies 68
4.2.1.2 Rising adoption of comprehensive genomic profiling and
NGS-based testing 69
4.2.1.3 Increasing cancer incidence and demand for molecular characterization 69
4.2.2 RESTRAINTS 70
4.2.2.1 High development, clinical validation, and regulatory approval costs 70
4.2.3 OPPORTUNITIES 71
4.2.3.1 Expansion of liquid biopsy and minimally invasive tumor profiling 71
4.2.3.2 AI-driven biomarker interpretation and digital pathology integration 71
4.2.4 CHALLENGES 72
4.2.4.1 Regulatory complexity associated with multi-analyte tumor profiling tests 72
4.3 UNMET NEEDS & WHITE SPACES 72
4.3.1 UNMET NEEDS IN CANCER/TUMOR PROFILING MARKET 72
4.3.2 WHITE SPACE OPPORTUNITIES 73
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 75
4.4.1 INTERCONNECTED MARKETS 75
4.4.2 CROSS-SECTOR OPPORTUNITIES 75
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 76
4.5.1 KEY MOVES & STRATEGIC FOCUS 76
5 INDUSTRY TRENDS 77
5.1 PORTER’S FIVE FORCES ANALYSIS 77
5.1.1 BARGAINING POWER OF SUPPLIERS 78
5.1.2 BARGAINING POWER OF BUYERS 78
5.1.3 THREAT OF NEW ENTRANTS 78
5.1.4 THREAT OF SUBSTITUTES 78
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.2 MACROECONOMIC INDICATORS 79
5.2.1 INTRODUCTION 79
5.2.2 GDP TRENDS & FORECAST 79
5.2.3 TRENDS IN GLOBAL CANCER/TUMOR PROFILING INDUSTRY 82
5.3 SUPPLY CHAIN ANALYSIS 83
5.4 VALUE CHAIN ANALYSIS 85
5.5 ECOSYSTEM ANALYSIS 87
5.5.1 CANCER/TUMOR PROFILING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING
OFFERING, BY KEY PLAYER, 2024–2026 89
5.6.2 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING
OFFERING, BY REGION, 2024–2026 90
5.7 TRADE ANALYSIS 91
5.7.1 IMPORT SCENARIO (HS CODE 3822) 91
5.7.2 EXPORT SCENARIO (HS CODE 3822) 92
5.8 KEY CONFERENCES & EVENTS, 2026–2027 92
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.10 INVESTMENT & FUNDING SCENARIO 94
5.11 IMPACT OF 2025 US TARIFFS ON COMPANION DIAGNOSTICS MARKET 95
5.11.1 INTRODUCTION 95
5.11.2 KEY TARIFF RATES 96
5.11.3 PRICE IMPACT ANALYSIS 96
5.11.4 IMPACT ON REGIONS 97
5.11.4.1 North America 97
5.11.4.2 Europe 98
5.11.4.3 Asia Pacific 98
5.11.5 IMPACT ON END-USE INDUSTRIES 98
5.11.5.1 Hospitals, Cancer Centers, and Oncology Clinics 98
5.11.5.2 Independent and Specialty Reference Laboratories 98
5.11.5.3 Pharmaceutical and Biotechnology Companies 99
5.11.5.4 Other end user 99
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 100
6.1 KEY EMERGING TECHNOLOGIES 100
6.1.1 HIGH-SENSITIVITY LIQUID BIOPSY AND ERROR-CORRECTED SEQUENCING 100
6.1.2 SPATIAL, SINGLE-CELL, AND MULTIPLEX TISSUE PROFILING 100
6.2 COMPLEMENTARY TECHNOLOGIES 100
6.2.1 AI-ENABLED BIOINFORMATICS AND CLINICAL DECISION SUPPORT 100
6.2.2 DIGITAL PATHOLOGY AND IMAGE ANALYSIS 100
6.3 ADJACENT TECHNOLOGIES 101
6.3.1 MOLECULAR IMAGING AND RADIOMICS 101
6.4 TECHNOLOGY/PRODUCT ROADMAP 101
6.5 PATENT ANALYSIS 103
6.6 FUTURE APPLICATIONS 103
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER/TUMOR PROFILING MARKET 104
6.7.1 INTRODUCTION 104
6.7.2 TOP USE CASES & MARKET POTENTIAL 105
6.7.3 KEY COMPANIES IMPLEMENTING AI 105
6.7.4 FUTURE OF AI 106
7 SUSTAINABILITY & REGULATORY LANDSCAPE 108
7.1 REGIONAL REGULATIONS & COMPLIANCE 108
7.1.1 REGULATORY ANALYSIS 108
7.1.1.1 North America 108
7.1.1.1.1 US 108
7.1.1.1.2 Canada 109
7.1.1.2 Europe 109
7.1.1.2.1 Germany 110
7.1.1.2.2 UK 110
7.1.1.2.3 France 110
7.1.1.2.4 Italy 111
7.1.1.3 Asia Pacific 111
7.1.1.3.1 China 111
7.1.1.3.2 Japan 111
7.1.1.3.3 India 112
7.1.1.3.4 Australia 112
7.1.1.4 Latin America 113
7.1.1.4.1 Brazil 113
7.1.1.4.2 Mexico 113
7.1.1.5 Middle East 113
7.1.1.5.1 Africa 114
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114
7.2 SUSTAINABILITY INITIATIVES 116
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 116
7.2.1.1 Eco-friendly initiatives 116
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 116
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 118
8.1 DECISION-MAKING PROCESS 118
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 119
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 119
8.2.2 BUYING CRITERIA 120
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 120
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 122
8.5 MARKET PROFITABILITY 123
8.5.1 REVENUE POTENTIAL 123
8.5.2 COST DYNAMICS 123
9 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING 125
9.1 INTRODUCTION 126
9.2 PRODUCTS 126
9.2.1 INSTRUMENTS AND SYSTEMS 130
9.2.1.1 Decentralized molecular testing and pressure to cut turnaround time to drive instrument demand 130
9.2.2 ASSAYS, KITS, REAGENTS, AND CONSUMABLES 133
9.2.2.1 Recurring-use model to link procedure volume directly to revenue 133
9.3 SERVICES 137
9.3.1 CLINICAL TUMOR PROFILING TESTING SERVICES 140
9.3.1.1 Rising clinical oncology tests and high selling prices to drive services growth 140
9.3.2 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES 144
9.3.2.1 Expanding oncology drug development to require broader biomarker adoption 144
10 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE 148
10.1 INTRODUCTION 149
10.2 TISSUE SAMPLES 150
10.2.1 TISSUE BIOPSY 150
10.3 BLOOD SAMPLES 153
10.3.1 LIQUID BIOPSY 153
10.4 BONE MARROW 156
10.4.1 RESEARCH AND CLINICAL-TRIAL SPECIMENS 156
10.5 OTHER SAMPLE TYPES 160
11 CANCER/TUMOR PROFILING MARKET, BY APPLICATION 164
11.1 INTRODUCTION 165
11.2 CLINICAL APPLICATIONS 165
11.2.1 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT 169
11.2.1.1 Integration of multi-omic biomarkers to redefine tumor diagnosis and classification 169
11.2.2 TREATMENT SELECTION AND COMPANION DIAGNOSTICS 173
11.2.2.1 Expanding targeted-therapy pipelines and pharma–diagnostic partnerships to drive companion diagnostics 173
11.2.3 TREATMENT-RESPONSE AND RESISTANCE MONITORING 176
11.2.3.1 Growing on-therapy profiling to monitor response and emerging resistance 176
11.2.4 RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION 180
11.2.4.1 Rising molecular residual disease testing to detect recurrence early 180
11.3 RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS 183
11.3.1 BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY 187
11.3.1.1 Wider use of whole-exome, transcriptome, and proteomic profiling to accelerate drug discovery 187
11.3.2 PRECLINICAL DEVELOPMENT AND VALIDATION 190
11.3.2.1 Molecular profiling of preclinical models to validate targets and characterize resistance 190
11.3.3 CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT 193
11.3.3.1 Growing number of oncology clinical trials to
embed biomarker profiling 193
12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE 197
12.1 INTRODUCTION 198
12.2 SOLID TUMORS 198
12.2.1 LUNG CANCER 202
12.2.1.1 Broad actionable biomarkers to drive high molecular testing in lung cancer 202
12.2.2 BREAST CANCER 205
12.2.2.1 High incidence and complex molecular classification to expand breast cancer profiling 205
12.2.3 COLORECTAL CANCER 208
12.2.3.1 Established biomarkers and emerging MRD testing to expand colorectal cancer profiling 208
12.2.4 PROSTATE CANCER 211
12.2.4.1 Growing HRR-targeted therapies to broaden profiling in metastatic prostate cancer 211
12.2.5 GYNECOLOGIC CANCERS 214
12.2.5.1 HRD/BRCA testing and endometrial molecular stratification to drive gynecologic profiling 214
12.2.6 MELANOMA 217
12.2.6.1 BRAF testing and immunotherapy biomarkers to sustain melanoma profiling 217
12.2.7 BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS 220
12.2.7.1 Molecular criteria in WHO definitions to make profiling essential for CNS tumors 220
12.2.8 HEAD AND NECK CANCERS 223
12.2.8.1 Rising immunotherapy use and PD-L1 testing to expand head and neck cancer profiling 223
12.2.9 OTHER SOLID TUMORS 226
12.3 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES 229
12.3.1 LEUKEMIA 233
12.3.1.1 Routine molecular diagnosis and frequent MRD monitoring
to drive leukemia profiling 233
12.3.2 LYMPHOMAS 236
12.3.2.1 Complex classification and growing genomic testing to broaden lymphoma profiling 236
12.3.3 MULTIPLE MYELOMA AND OTHER LIQUID TUMORS 239
12.3.3.1 NGS and sensitive MRD assays to create repeat testing in multiple myeloma 239
13 CANCER/TUMOR PROFILING MARKET, BY END USER 243
13.1 INTRODUCTION 244
13.2 HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS 245
13.2.1 MULTISPECIALTY HOSPITALS 248
13.2.1.1 Growing integration of biomarker testing to embed profiling in hospital oncology pathways 248
13.2.2 DEDICATED CANCER HOSPITALS AND CANCER CENTERS 251
13.2.2.1 High oncology volumes and research programs to drive profiling at cancer centers 251
13.3 INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES 254
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 257
13.5 CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES 260
13.6 OTHER END USERS 263
14 CANCER/TUMOR PROFILING MARKET, BY REGION 267
14.1 INTRODUCTION 268
14.2 NORTH AMERICA 268
14.2.1 US 277
14.2.1.1 Advanced clinical genomics infrastructure and broad regulatory approvals to augment market growth 277
14.2.2 CANADA 284
14.2.2.1 Public funding of molecular profiling and expansion of national genomics capabilities to support growth 284
14.3 EUROPE 291
14.3.1 GERMANY 299
14.3.1.1 Strong molecular tumor board networks and multi-omic precision oncology infrastructure to drive adoption 299
14.3.2 UK 306
14.3.2.1 NHS-funded genomic testing and centralized genomic laboratory network to support market maturity 306
14.3.3 FRANCE 313
14.3.3.1 National genomic medicine infrastructure to accelerate tumor profiling 313
14.3.4 ITALY 320
14.3.4.1 Public funding for NGS and genomic testing to support precision-oncology expansion 320
14.3.5 SPAIN 327
14.3.5.1 National genomic test catalog and strong oncology research network to support market growth 327
14.3.6 REST OF EUROPE 334
14.4 ASIA PACIFIC 341
14.4.1 CHINA 350
14.4.1.1 Large cancer burden and formalization of clinical NGS standards to drive market expansion 350
14.4.2 JAPAN 357
14.4.2.1 National insurance coverage and C-CAT infrastructure to support broad CGP adoption 357
14.4.3 INDIA 364
14.4.3.1 Rising cancer burden and expansion of indigenous genomic infrastructure to support high growth 364
14.4.4 SOUTH KOREA 371
14.4.4.1 Government-backed NGS precision-oncology programs to accelerate clinical adoption 371
14.4.5 AUSTRALIA 378
14.4.5.1 National genomics framework and government investments to strengthen precision oncology 378
14.4.6 REST OF ASIA PACIFIC 385
14.5 LATIN AMERICA 392
14.5.1 BRAZIL 400
14.5.1.1 National genomics program and local tumor atlas development to accelerate precision oncology 400
14.5.2 MEXICO 407
14.5.2.1 Expansion of national cancer genotyping infrastructure to support market development 407
14.5.3 REST OF LATIN AMERICA 414
14.6 MIDDLE EAST & AFRICA 421
14.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 421
14.7 GCC COUNTRIES 428
14.7.1 GOVERNMENT-LED GENOMICS AND PRECISION-MEDICINE INVESTMENTS TO CREATE HIGH-GROWTH OPPORTUNITIES 428
14.8 REST OF MIDDLE EAST & AFRICA 435
14.8.1 LARGE UNMET NEED FOR BIOMARKER TESTING AND GRADUAL BUILD-OUT OF MOLECULAR ONCOLOGY CAPACITY 435
15 COMPETITIVE LANDSCAPE 442
15.1 INTRODUCTION 442
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 442
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER/TUMOR PROFILING MARKET 442
15.3 REVENUE ANALYSIS, 2023–2025 445
15.4 MARKET SHARE ANALYSIS, 2025 446
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 447
15.5.1 STARS 447
15.5.2 EMERGING LEADERS 447
15.5.3 PERVASIVE PLAYERS 447
15.5.4 PARTICIPANTS 448
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 449
15.5.5.1 Company footprint 449
15.5.5.2 Regional footprint 449
15.5.5.3 Product & service footprint 450
15.5.5.4 Technology footprint 451
15.5.5.5 Sample Type footprint 452
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 453
15.6.1 PROGRESSIVE COMPANIES 453
15.6.2 RESPONSIVE COMPANIES 453
15.6.3 DYNAMIC COMPANIES 453
15.6.4 STARTING BLOCKS 453
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 455
15.6.5.1 Detailed list of key startups/SMEs 455
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 455
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 456
15.7 COMPANY VALUATION & FINANCIAL METRICS 456
15.7.1 FINANCIAL METRICS 456
15.7.2 COMPANY VALUATION 457
15.8 BRAND/PRODUCT COMPARISON 458
15.9 COMPETITIVE SCENARIO 459
15.9.1 PRODUCT LAUNCHES & APPROVALS 459
15.9.2 DEALS 466
15.9.3 EXPANSIONS 475
15.9.4 OTHER DEVELOPMENTS 476
16 COMPANY PROFILES 477
16.1 KEY PLAYERS 477
16.1.1 F. HOFFMANN-LA ROCHE LTD. 477
16.1.1.1 Business overview 477
16.1.1.2 Products offered 478
16.1.1.3 Recent developments 480
16.1.1.3.1 Product launches & approvals 480
16.1.1.3.2 Deals 481
16.1.1.3.3 Expansions 481
16.1.1.4 MnM view 482
16.1.1.4.1 Key strengths 482
16.1.1.4.2 Strategic choices 482
16.1.1.4.3 Weaknesses & competitive threats 482
16.1.2 ILLUMINA, INC. 483
16.1.2.1 Business overview 483
16.1.2.2 Products offered 484
16.1.2.3 Recent developments 485
16.1.2.3.1 Product launches & approvals 485
16.1.2.3.2 Deals 486
16.1.2.3.3 Other developments 486
16.1.2.4 MnM view 486
16.1.2.4.1 Key strengths 486
16.1.2.4.2 Strategic choices 487
16.1.2.4.3 Weaknesses & competitive threats 487
16.1.3 THERMO FISHER SCIENTIFIC INC. 488
16.1.3.1 Business overview 488
16.1.3.2 Products offered 489
16.1.3.3 Recent developments 490
16.1.3.3.1 Product launches 490
16.1.3.3.2 Deals 490
16.1.3.4 MnM view 491
16.1.3.4.1 Key strengths 491
16.1.3.4.2 Strategic choices 491
16.1.3.4.3 Weaknesses & competitive threats 491
16.1.4 QIAGEN 492
16.1.4.1 Business overview 492
16.1.4.2 Products offered 494
16.1.4.3 Recent developments 495
16.1.4.3.1 Product launches & approvals 495
16.1.4.3.2 Deals 495
16.1.4.3.3 Expansions 496
16.1.4.4 MnM view 496
16.1.4.4.1 Key strengths 496
16.1.4.4.2 Strategic choices 496
16.1.4.4.3 Weaknesses & competitive threats 497
16.1.5 GUARDANT HEALTH 498
16.1.5.1 Business overview 498
16.1.5.2 Products offered 499
16.1.5.3 Recent developments 500
16.1.5.3.1 Product launches & approvals 500
16.1.5.4 MnM view 502
16.1.5.4.1 Key strengths 502
16.1.5.4.2 Strategic choices 503
16.1.5.4.3 Weaknesses & competitive threats 503
16.1.6 LABCORP 504
16.1.6.1 Business overview 504
16.1.6.2 Product & Services offered 505
16.1.6.3 Recent developments 506
16.1.6.3.1 Service Launches, and Approvals 506
16.1.6.3.2 Deals 507
16.1.6.3.3 Expansions 507
16.1.7 ABBOTT 508
16.1.7.1 Business overview 508
16.1.7.2 Products offered 510
16.1.7.3 Recent developments 510
16.1.7.3.1 Product approvals 510
16.1.7.3.2 Deals 511
16.1.8 TEMPUS AI, INC. 512
16.1.8.1 Business overview 512
16.1.8.2 Products offered 513
16.1.8.3 Recent developments 513
16.1.8.3.1 Product approvals 513
16.1.8.3.2 Deals 514
16.1.8.3.3 Other developments 514
16.1.9 NATERA, INC. 515
16.1.9.1 Business overview 515
16.1.9.2 Products offered 516
16.1.9.3 Recent developments 517
16.1.9.3.1 Product launches & Approvals 517
16.1.9.3.2 Deals 518
16.1.9.3.3 Expansions 518
16.1.9.3.4 Other developments 519
16.1.10 NEOGENOMICS LABORATORIES, INC 520
16.1.10.1 Business overview 520
16.1.10.2 Products offered 521
16.1.10.3 Recent developments 521
16.1.10.3.1 Product launches & approvals 521
16.1.10.3.2 Deals 522
16.1.10.3.3 Expansions 522
16.1.11 MYRIAD GENETICS, INC. 523
16.1.11.1 Business overview 523
16.1.11.2 Products offered 524
16.1.11.3 Recent developments 525
16.1.11.3.1 Product launches & approvals 525
16.1.11.3.2 Deals 526
16.1.12 AGILENT TECHNOLOGIES, INC 528
16.1.12.1 Business overview 528
16.1.12.2 Products offered 529
16.1.12.3 Recent developments 531
16.1.12.3.1 Product launches & approvals 531
16.1.12.3.2 Deals 532
16.1.12.3.3 Expansions 532
16.1.13 QUEST DIAGNOSTICS 533
16.1.13.1 Business overview 533
16.1.13.2 Products/Services/Solutions offered 534
16.1.13.3 Recent developments 535
16.1.13.3.1 Product/Services launches & approvals 535
16.1.13.3.2 Deals 535
16.1.14 CARIS LIFE SCIENCES, INC. 537
16.1.14.1 Business overview 537
16.1.14.2 Products offered 538
16.1.14.3 Recent developments 539
16.1.14.3.1 Product launches & approvals 539
16.1.14.3.2 Deals 540
16.1.15 DANAHER 541
16.1.15.1 Business overview 541
16.1.15.2 Products offered 543
16.1.15.3 Recent developments 544
16.1.15.3.1 Deals 544
16.2 OTHER PLAYERS 545
16.2.1 INSIGHT MOLECULAR DIAGNOSTICS, INC (IMDX) (ONCOCYTE CORPORATION) 545
16.2.2 ONCODNA SA 546
16.2.3 MOLECULAR HEALTH GMBH 547
16.2.4 ALMAC DIAGNOSTIC SERVICES (THE ALMAC GROUP) 548
16.2.5 INVIVOSCRIBE, INC. 549
16.2.6 ACT GENOMICS CO., LTD. 550
16.2.7 LUCENCE HEALTH INC 551
16.2.8 GC GENOME CORPORATION 552
16.2.9 MEDGENOME LABS LTD. 553
16.2.10 MGI TECH CO., LTD. 554
17 RESEARCH METHODOLOGY 555
17.1 RESEARCH DATA 555
17.1.1 SECONDARY DATA 556
17.1.1.1 List of secondary sources 556
17.1.1.2 Key data from secondary sources 557
17.1.2 PRIMARY DATA 557
17.1.2.1 List of primary sources 558
17.1.2.2 Key data from primary sources 558
17.1.2.3 Key industry insights 560
17.1.2.4 Breakdown of primary interviews 560
17.2 MARKET SIZE ESTIMATION 561
17.2.1 TOTAL MARKET SIZE: CANCER/TUMOR PROFILING MARKET 561
17.2.2 BOTTOM-UP APPROACH 561
17.2.2.1 Approach 1: Revenue estimation of key players 561
17.2.2.2 Approach 2: Study of annual reports and investor presentations 562
17.2.2.3 Approach 3: Primary interviews 562
17.2.2.4 Growth forecast 562
17.2.3 TOP-DOWN APPROACH 564
17.3 DATA TRIANGULATION 565
17.4 RESEARCH ASSUMPTIONS 566
17.4.1 STUDY-RELATED ASSUMPTIONS 566
17.4.2 GROWTH RATE ASSUMPTIONS 567
17.5 RESEARCH LIMITATIONS 568
17.6 RISK ASSESSMENT 568
18 APPENDIX 569
18.1 DISCUSSION GUIDE 569
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 575
18.3 CUSTOMIZATION OPTIONS 577
18.4 RELATED REPORTS 577
18.5 AUTHOR DETAILS 578
圖表清單 List of Tables & Figures
TABLE 1 INCLUSIONS & EXCLUSIONS 51
TABLE 2 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS 78
TABLE 3 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2023–2030 80
TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS 81
TABLE 5 EUROPE: MACROECONOMIC INDICATORS 81
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS 81
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS 82
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 82
TABLE 9 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING,
BY KEY PLAYER, 2024–2026 (USD) 89
TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS,
BY REGION, 2024–2026 (USD) 90
TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 91
TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 92
TABLE 13 CANCER/TUMOR PROFILING MARKET: KEY CONFERENCES & EVENTS, 2026–2027 93
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN CANCER/TUMOR PROFILING MARKET 106
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE 109
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 111
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA 112
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 114
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 115
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 119
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 120
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
TABLE 27 CANCER/TUMOR PROFILING MARKET: UNMET NEEDS IN VARIOUS
END-USE INDUSTRIES 122
TABLE 28 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING,
2024–2031 (USD MILLION) 126
TABLE 29 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 30 NORTH AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 31 EUROPE: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 128
TABLE 32 ASIA PACIFIC: CANCER/TUMOR PROFILING PRODUCTS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 128
TABLE 33 LATIN AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 129
TABLE 34 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING PRODUCTS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 129
TABLE 35 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 130
TABLE 36 CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 38 EUROPE: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 132
TABLE 39 ASIA PACIFIC: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 132
TABLE 40 LATIN AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133
TABLE 41 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133
TABLE 42 CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 43 NORTH AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 44 EUROPE: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 135
TABLE 45 ASIA PACIFIC: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 136
TABLE 46 LATIN AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 136
TABLE 47 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137
TABLE 48 CANCER/TUMOR PROFILING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 137
TABLE 49 NORTH AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 50 EUROPE: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 138
TABLE 51 ASIA PACIFIC: CANCER/TUMOR PROFILING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 139
TABLE 52 LATIN AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 139
TABLE 53 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 140
TABLE 54 CANCER/TUMOR PROFILING SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 140
TABLE 55 CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 141
TABLE 56 NORTH AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 57 EUROPE: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 142
TABLE 58 ASIA PACIFIC: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 143
TABLE 59 LATIN AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 143
TABLE 60 MIDDLE EAST & AFRICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 144
TABLE 61 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 62 NORTH AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 63 EUROPE: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 146
TABLE 64 ASIA PACIFIC: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 146
TABLE 65 LATIN AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 147
TABLE 66 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 147
TABLE 67 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 149
TABLE 68 CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 70 EUROPE: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 151
TABLE 71 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 152
TABLE 72 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 152
TABLE 73 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 153
TABLE 74 CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY REGION,
2024–2031 (USD MILLION) 154
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 76 EUROPE: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 155
TABLE 77 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 155
TABLE 78 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 156
TABLE 79 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 156
TABLE 80 CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY REGION,
2024–2031 (USD MILLION) 157
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 82 EUROPE: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 158
TABLE 83 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 159
TABLE 84 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 159
TABLE 85 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 160
TABLE 86 CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 87 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 88 EUROPE: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 162
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 162
TABLE 90 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 163
TABLE 91 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 163
TABLE 92 CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 165
TABLE 93 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY REGION, 2024–2031 (USD MILLION) 166
TABLE 94 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 167
TABLE 96 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 167
TABLE 97 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 168
TABLE 98 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 168
TABLE 99 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 169
TABLE 100 CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 101 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 171
TABLE 103 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 171
TABLE 104 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 172
TABLE 105 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 172
TABLE 106 CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 107 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 108 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 174
TABLE 109 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 175
TABLE 110 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 175
TABLE 111 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 176
TABLE 112 CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY REGION, 2024–2031 (USD MILLION) 177
TABLE 113 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 178
TABLE 115 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 178
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 179
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 179
TABLE 118 CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 119 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 181
TABLE 121 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 182
TABLE 122 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 182
TABLE 123 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 183
TABLE 124 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 125 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 126 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 185
TABLE 127 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 185
TABLE 128 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 186
TABLE 129 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 186
TABLE 130 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 187
TABLE 131 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 132 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 133 EUROPE: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 189
TABLE 134 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 189
TABLE 135 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 190
TABLE 136 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/ REGION,
2024–2031 (USD MILLION) 190
TABLE 137 CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 138 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 139 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 192
TABLE 140 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 192
TABLE 141 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 193
TABLE 142 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 193
TABLE 143 CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 144 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 145 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 195
TABLE 146 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 195
TABLE 147 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 196
TABLE 148 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 196
TABLE 149 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 198
TABLE 150 SOLID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 199
TABLE 151 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 152 EUROPE: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 200
TABLE 153 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 200
TABLE 154 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 201
TABLE 155 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/ REGION, 2024–2031 (USD MILLION) 201
TABLE 156 SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 202
TABLE 157 LUNG CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 203
TABLE 158 NORTH AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 159 EUROPE: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 204
TABLE 160 ASIA PACIFIC: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 204
TABLE 161 LATIN AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 205
TABLE 162 MIDDLE EAST & AFRICA: LUNG CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 205
TABLE 163 BREAST CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 164 NORTH AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 206
TABLE 165 EUROPE: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 207
TABLE 166 ASIA PACIFIC: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 207
TABLE 167 LATIN AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 208
TABLE 168 MIDDLE EAST & AFRICA: BREAST CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 208
TABLE 169 COLORECTAL CANCER PROFILING MARKET, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 170 NORTH AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 171 EUROPE: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 210
TABLE 172 ASIA PACIFIC: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 210
TABLE 173 LATIN AMERICA: COLORECTAL CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 211
TABLE 174 MIDDLE EAST & AFRICA: COLORECTAL CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 211
TABLE 175 PROSTATE CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 176 NORTH AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 212
TABLE 177 EUROPE: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 213
TABLE 178 ASIA PACIFIC: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 213
TABLE 179 LATIN AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 214
TABLE 180 MIDDLE EAST & AFRICA: PROSTATE CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 214
TABLE 181 GYNECOLOGIC CANCERS PROFILING MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 182 NORTH AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 183 EUROPE: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 216
TABLE 184 ASIA PACIFIC: GYNECOLOGIC CANCERS PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 216
TABLE 185 LATIN AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 217
TABLE 186 MIDDLE EAST & AFRICA: GYNECOLOGIC CANCERS PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 217
TABLE 187 MELANOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 188 NORTH AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 189 EUROPE: MELANOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 219
TABLE 190 ASIA PACIFIC: MELANOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 219
TABLE 191 LATIN AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 220
TABLE 192 MIDDLE EAST & AFRICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 220
TABLE 193 BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 194 NORTH AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 195 EUROPE: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 222
TABLE 196 ASIA PACIFIC: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 222
TABLE 197 LATIN AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 223
TABLE 198 MIDDLE EAST & AFRICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 223
TABLE 199 HEAD AND NECK CANCER PROFILING MARKET, BY REGION,
2024–2031 (USD MILLION) 224
TABLE 200 NORTH AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 201 EUROPE: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 225
TABLE 202 ASIA PACIFIC: HEAD AND NECK CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 225
TABLE 203 LATIN AMERICA: HEAD AND NECK CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 226
TABLE 204 MIDDLE EAST & AFRICA: HEAD AND NECK CANCER PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 226
TABLE 205 OTHER SOLID TUMOR PROFILING MARKET, BY REGION,
2024–2031 (USD MILLION) 227
TABLE 206 NORTH AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 207 EUROPE: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 228
TABLE 208 ASIA PACIFIC: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 228
TABLE 209 LATIN AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 229
TABLE 210 MIDDLE EAST & AFRICA: OTHER SOLID TUMOR PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 229
TABLE 211 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET,
BY REGION, 2024–2031 (USD MILLION) 230
TABLE 212 NORTH AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 213 EUROPE: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 231
TABLE 214 ASIA PACIFIC: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 231
TABLE 215 LATIN AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 232
TABLE 216 MIDDLE EAST & AFRICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 232
TABLE 217 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET,
BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 218 LEUKEMIA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 234
TABLE 219 NORTH AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 220 EUROPE: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 235
TABLE 221 ASIA PACIFIC: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 235
TABLE 222 LATIN AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 236
TABLE 223 MIDDLE EAST & AFRICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 236
TABLE 224 LYMPHOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 237
TABLE 225 NORTH AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 237
TABLE 226 EUROPE: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 238
TABLE 227 ASIA PACIFIC: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 238
TABLE 228 LATIN AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 239
TABLE 229 MIDDLE EAST & AFRICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 239
TABLE 230 MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 231 NORTH AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 232 EUROPE: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 241
TABLE 233 ASIA PACIFIC: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 241
TABLE 234 LATIN AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 242
TABLE 235 MIDDLE EAST & AFRICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 242
TABLE 236 CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION) 244
TABLE 237 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS,
AND ONCOLOGY CLINICS, BY REGION, 2024–2031 (USD MILLION) 245
TABLE 238 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 239 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 246
TABLE 240 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 247
TABLE 241 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 247
TABLE 242 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 248
TABLE 243 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS,
AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 244 CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS,
BY REGION, 2024–2031 (USD MILLION) 249
TABLE 245 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 246 EUROPE: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 250
TABLE 247 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 250
TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 251
TABLE 249 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 251
TABLE 250 CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY REGION, 2024–2031 (USD MILLION) 252
TABLE 251 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 252 EUROPE: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 253
TABLE 253 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 253
TABLE 254 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 254
TABLE 255 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 254
TABLE 256 CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 255
TABLE 257 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 258 EUROPE: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 256
TABLE 259 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 256
TABLE 260 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 257
TABLE 261 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 257
TABLE 262 CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 263 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 264 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 259
TABLE 265 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 259
TABLE 266 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 260
TABLE 267 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/
REGION, 2024–2031 (USD MILLION) 260
TABLE 268 CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 261
TABLE 269 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 261
TABLE 270 EUROPE: CANCER/TUMOR PROFILING MARKET CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 262
TABLE 271 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 262
TABLE 272 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 263
TABLE 273 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 263
TABLE 274 CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 264
TABLE 275 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 276 EUROPE: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 265
TABLE 277 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 265
TABLE 278 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 266
TABLE 279 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR
OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 266
TABLE 280 CANCER/TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION) 268
TABLE 281 NORTH AMERICA: MACROECONOMIC INDICATORS 270
TABLE 282 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 270
TABLE 283 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 270
TABLE 284 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 271
TABLE 285 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 271
TABLE 286 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 272
TABLE 287 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 272
TABLE 288 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 273
TABLE 289 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 273
TABLE 290 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 274
TABLE 291 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 274
TABLE 292 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 275
TABLE 293 NORTH AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 275
TABLE 294 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 276
TABLE 295 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 296 US: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 277
TABLE 297 US: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 278
TABLE 298 US: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 278
TABLE 299 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 279
TABLE 300 US: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 279
TABLE 301 US: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 280
TABLE 302 US: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 280
TABLE 303 US: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 281
TABLE 304 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 281
TABLE 305 US: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 282
TABLE 306 US: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 282
TABLE 307 US: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 283
TABLE 308 US: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 309 CANADA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 284
TABLE 310 CANADA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 285
TABLE 311 CANADA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 285
TABLE 312 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 286
TABLE 313 CANADA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 286
TABLE 314 CANADA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 287
TABLE 315 CANADA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 287
TABLE 316 CANADA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 288
TABLE 317 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 288
TABLE 318 CANADA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 289
TABLE 319 CANADA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 289
TABLE 320 CANADA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 290
TABLE 321 CANADA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 322 EUROPE: MACROECONOMIC INDICATORS 291
TABLE 323 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 291
TABLE 324 EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 292
TABLE 325 EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 292
TABLE 326 EUROPE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 293
TABLE 327 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 293
TABLE 328 EUROPE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 294
TABLE 329 EUROPE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 294
TABLE 330 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 295
TABLE 331 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 296
TABLE 332 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 296
TABLE 333 EUROPE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 297
TABLE 334 EUROPE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 297
TABLE 335 EUROPE: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 298
TABLE 336 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 337 GERMANY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 299
TABLE 338 GERMANY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 300
TABLE 339 GERMANY: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 300
TABLE 340 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 301
TABLE 341 GERMANY: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 301
TABLE 342 GERMANY: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 302
TABLE 343 GERMANY: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 302
TABLE 344 GERMANY: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 303
TABLE 345 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 303
TABLE 346 GERMANY: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 304
TABLE 347 GERMANY: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 304
TABLE 348 GERMANY: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 305
TABLE 349 GERMANY: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 350 UK: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 306
TABLE 351 UK: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 307
TABLE 352 UK: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 307
TABLE 353 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 308
TABLE 354 UK: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 308
TABLE 355 UK: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 309
TABLE 356 UK: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 309
TABLE 357 UK: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 310
TABLE 358 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 310
TABLE 359 UK: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 311
TABLE 360 UK: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 311
TABLE 361 UK: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 312
TABLE 362 UK: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 363 FRANCE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 313
TABLE 364 FRANCE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 314
TABLE 365 FRANCE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 314
TABLE 366 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 315
TABLE 367 FRANCE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 315
TABLE 368 FRANCE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 316
TABLE 369 FRANCE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 316
TABLE 370 FRANCE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 317
TABLE 371 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 317
TABLE 372 FRANCE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 318
TABLE 373 FRANCE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 318
TABLE 374 FRANCE: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 319
TABLE 375 FRANCE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 376 ITALY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 320
TABLE 377 ITALY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 321
TABLE 378 ITALY: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 321
TABLE 379 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 322
TABLE 380 ITALY: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 322
TABLE 381 ITALY: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 323
TABLE 382 ITALY: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 323
TABLE 383 ITALY: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 324
TABLE 384 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 324
TABLE 385 ITALY: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 325
TABLE 386 ITALY: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 325
TABLE 387 ITALY: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 326
TABLE 388 ITALY: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 389 SPAIN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 327
TABLE 390 SPAIN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 328
TABLE 391 SPAIN: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 328
TABLE 392 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 329
TABLE 393 SPAIN: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 329
TABLE 394 SPAIN: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 330
TABLE 395 SPAIN: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 330
TABLE 396 SPAIN: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 331
TABLE 397 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 331
TABLE 398 SPAIN: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 332
TABLE 399 SPAIN: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 332
TABLE 400 SPAIN: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 333
TABLE 401 SPAIN: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 402 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET,
BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 334
TABLE 403 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET,
BY PRODUCT TYPE, 2024–2031 (USD MILLION) 334
TABLE 404 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 335
TABLE 405 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 335
TABLE 406 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 336
TABLE 407 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 336
TABLE 408 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 337
TABLE 409 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 338
TABLE 410 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 338
TABLE 411 REST OF EUROPE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 339
TABLE 412 REST OF EUROPE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 339
TABLE 413 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 340
TABLE 414 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 415 ASIA PACIFIC: MACROECONOMIC INDICATORS 342
TABLE 416 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 342
TABLE 417 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT &
SERVICE OFFERING, 2024–2031 (USD MILLION) 343
TABLE 418 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 343
TABLE 419 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 344
TABLE 420 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 344
TABLE 421 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 345
TABLE 422 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 345
TABLE 423 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 346
TABLE 424 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 347
TABLE 425 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 347
TABLE 426 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 348
TABLE 427 ASIA PACIFIC: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 348
TABLE 428 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 349
TABLE 429 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 430 CHINA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 350
TABLE 431 CHINA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 351
TABLE 432 CHINA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 351
TABLE 433 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 352
TABLE 434 CHINA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 352
TABLE 435 CHINA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 353
TABLE 436 CHINA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 353
TABLE 437 CHINA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 354
TABLE 438 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 354
TABLE 439 CHINA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 355
TABLE 440 CHINA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 355
TABLE 441 CHINA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 356
TABLE 442 CHINA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 443 JAPAN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 357
TABLE 444 JAPAN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 358
TABLE 445 JAPAN: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 358
TABLE 446 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 359
TABLE 447 JAPAN: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 359
TABLE 448 JAPAN: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 360
TABLE 449 JAPAN: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 360
TABLE 450 JAPAN: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 361
TABLE 451 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 361
TABLE 452 JAPAN: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 362
TABLE 453 JAPAN: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 362
TABLE 454 JAPAN: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 363
TABLE 455 JAPAN: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 456 INDIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 364
TABLE 457 INDIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 365
TABLE 458 INDIA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 365
TABLE 459 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 366
TABLE 460 INDIA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 366
TABLE 461 INDIA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 367
TABLE 462 INDIA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 367
TABLE 463 INDIA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 368
TABLE 464 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 368
TABLE 465 INDIA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 369
TABLE 466 INDIA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 369
TABLE 467 INDIA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 370
TABLE 468 INDIA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 469 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 371
TABLE 470 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 372
TABLE 471 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 372
TABLE 472 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 373
TABLE 473 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 373
TABLE 474 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 374
TABLE 475 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 374
TABLE 476 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 375
TABLE 477 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 375
TABLE 478 SOUTH KOREA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 376
TABLE 479 SOUTH KOREA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 376
TABLE 480 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 377
TABLE 481 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 482 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 378
TABLE 483 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 379
TABLE 484 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 379
TABLE 485 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 380
TABLE 486 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 380
TABLE 487 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 381
TABLE 488 AUSTRALIA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 381
TABLE 489 AUSTRALIA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 382
TABLE 490 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 382
TABLE 491 AUSTRALIA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 383
TABLE 492 AUSTRALIA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 383
TABLE 493 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 384
TABLE 494 AUSTRALIA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 495 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 385
TABLE 496 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 386
TABLE 497 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 386
TABLE 498 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 387
TABLE 499 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 387
TABLE 500 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 388
TABLE 501 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 388
TABLE 502 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE,
2024–2031 (USD MILLION) 389
TABLE 503 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024–2031 (USD MILLION) 389
TABLE 504 REST OF ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 390
TABLE 505 REST OF ASIA PACIFIC: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 390
TABLE 506 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION) 391
TABLE 507 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 508 LATIN AMERICA: MACROECONOMIC INDICATORS 392
TABLE 509 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 392
TABLE 510 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 393
TABLE 511 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 393
TABLE 512 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 394
TABLE 513 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 394
TABLE 514 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 395
TABLE 515 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 395
TABLE 516 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 396
TABLE 517 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 397
TABLE 518 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 397
TABLE 519 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 398
TABLE 520 LATIN AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 398
TABLE 521 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 399
TABLE 522 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 523 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 400
TABLE 524 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 401
TABLE 525 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 401
TABLE 526 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 402
TABLE 527 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 402
TABLE 528 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 403
TABLE 529 BRAZIL: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 403
TABLE 530 BRAZIL: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 404
TABLE 531 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 404
TABLE 532 BRAZIL: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 405
TABLE 533 BRAZIL: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 405
TABLE 534 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 406
TABLE 535 BRAZIL: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 536 MEXICO: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 407
TABLE 537 MEXICO: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 408
TABLE 538 MEXICO: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 408
TABLE 539 MEXICO: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 409
TABLE 540 MEXICO: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 409
TABLE 541 MEXICO: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 410
TABLE 542 MEXICO: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS,
BY APPLICATION TYPE, 2024–2031 (USD MILLION) 410
TABLE 543 MEXICO: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 411
TABLE 544 MEXICO: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 411
TABLE 545 MEXICO: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 412
TABLE 546 MEXICO: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 412
TABLE 547 MEXICO: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 413
TABLE 548 MEXICO: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 549 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 414
TABLE 550 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 415
TABLE 551 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 415
TABLE 552 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 416
TABLE 553 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 416
TABLE 554 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 417
TABLE 555 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 417
TABLE 556 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE,
2024–2031 (USD MILLION) 418
TABLE 557 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024–2031 (USD MILLION) 418
TABLE 558 REST OF LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 419
TABLE 559 REST OF LATIN AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 419
TABLE 560 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION) 420
TABLE 561 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 562 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 421
TABLE 563 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 421
TABLE 564 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 422
TABLE 565 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 422
TABLE 566 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 423
TABLE 567 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 423
TABLE 568 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 424
TABLE 569 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 424
TABLE 570 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 425
TABLE 571 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024–2031 (USD MILLION) 425
TABLE 572 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 426
TABLE 573 MIDDLE EAST & AFRICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 426
TABLE 574 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION) 427
TABLE 575 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 576 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 428
TABLE 577 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 429
TABLE 578 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 429
TABLE 579 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 430
TABLE 580 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 430
TABLE 581 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 431
TABLE 582 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 431
TABLE 583 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 432
TABLE 584 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2024–2031 (USD MILLION) 432
TABLE 585 GCC COUNTRIES: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 433
TABLE 586 GCC COUNTRIES: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 433
TABLE 587 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY END USER,
2024–2031 (USD MILLION) 434
TABLE 588 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 589 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION) 435
TABLE 590 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY PRODUCT TYPE, 2024–2031 (USD MILLION) 436
TABLE 591 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 436
TABLE 592 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 437
TABLE 593 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 437
TABLE 594 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 438
TABLE 595 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 438
TABLE 596 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION) 439
TABLE 597 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY CANCER TYPE, 2024–2031 (USD MILLION) 439
TABLE 598 REST OF MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 440
TABLE 599 REST OF MIDDLE EAST & AFRICA: LIQUID TUMOR PROFILING MARKET,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 440
TABLE 600 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET,
BY END USER, 2024–2031 (USD MILLION) 441
TABLE 601 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE,
2024–2031 (USD MILLION) 441
TABLE 602 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CANCER/TUMOR PROFILING MARKET, JANUARY 2023−AUGUST 2026 442
TABLE 603 CANCER/TUMOR PROFILING MARKET: DEGREE OF COMPETITION 446
TABLE 604 CANCER/TUMOR PROFILING MARKET: REGIONAL FOOTPRINT 449
TABLE 605 CANCER/TUMOR PROFILING MARKET: PRODUCT & SERVICE FOOTPRINT 450
TABLE 606 CANCER/TUMOR PROFILING MARKET: TECHNOLOGY FOOTPRINT 451
TABLE 607 CANCER/TUMOR PROFILING MARKET: SAMPLE TYPE FOOTPRINT 452
TABLE 608 CANCER/TUMOR PROFILING MARKET: DETAILED LIST OF
KEY STARTUPS/SMES, 2025 455
TABLE 609 CANCER/TUMOR PROFILING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2), 2025 455
TABLE 610 CANCER/TUMOR PROFILING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2), 2025 456
TABLE 611 CANCER TUMOR PROFILING MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–AUGUST 2026 459
TABLE 612 CANCER/TUMOR PROFILING MARKET: DEALS, JANUARY 2023–MAY 2026 466
TABLE 613 CANCER/TUMOR PROFILING MARKET: EXPANSIONS,
JANUARY 2023–AUGUST 2026 475
TABLE 614 CANCER/TUMOR PROFILING MARKET: OTHER DEVELOPMENTS,
JANUARY 2023–AUGUST 2026 476
TABLE 615 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 477
TABLE 616 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 478
TABLE 617 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–AUGUST 2026 480
TABLE 618 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–AUGUST 2026 481
TABLE 619 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–AUGUST 2026 481
TABLE 620 ILLUMINA, INC.: COMPANY OVERVIEW 483
TABLE 621 ILLUMINA, INC.: PRODUCTS OFFERED 484
TABLE 622 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 485
TABLE 623 ILLUMINA, INC.: DEALS, JANUARY 2023–AUGUST 2026 486
TABLE 624 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 486
TABLE 625 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 488
TABLE 626 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 489
TABLE 627 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2023–AUGUST 2026 490
TABLE 628 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–AUGUST 2026 490
TABLE 629 QIAGEN: COMPANY OVERVIEW 492
TABLE 630 QIAGEN: PRODUCTS OFFERED 494
TABLE 631 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–AUGUST 2026 495
TABLE 632 QIAGEN: DEALS, JANUARY 2023–AUGUST 2026 495
TABLE 633 QIAGEN: EXPANSIONS, JANUARY 2023–AUGUST 2026 496
TABLE 634 GUARDANT HEALTH: COMPANY OVERVIEW 498
TABLE 635 GUARDANT HEALTH: PRODUCTS OFFERED 499
TABLE 636 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023-AUGUST 2026 500
TABLE 637 GUARDANT HEALTH: DEALS, JANUARY 2023-AUGUST 2026 501
TABLE 638 LABCORP: COMPANY OVERVIEW 504
TABLE 639 LABCORP: SERVICES OFFERED 505
TABLE 640 LABCORP: SERVICE LAUNCHES & APPROVALS, JANUARY 2023–AUGUST 2026 506
TABLE 641 LABCORP: DEALS, JANUARY 2023–AUGUST 2026 507
TABLE 642 LABCORP: EXPANSIONS, JANUARY 2023–AUGUST 2026 507
TABLE 643 ABBOTT: COMPANY OVERVIEW 508
TABLE 644 ABBOTT: PRODUCTS OFFERED 510
TABLE 645 ABBOTT: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 510
TABLE 646 ABBOTT: DEALS, JANUARY 2023–AUGUST 2026 511
TABLE 647 TEMPUS AI, INC.: COMPANY OVERVIEW 512
TABLE 648 TEMPUS AI, INC.: PRODUCTS OFFERED 513
TABLE 649 TEMPUS AI, INC: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 513
TABLE 650 TEMPUS AI, INC.: DEALS, JANUARY 2023–AUGUST 2026 514
TABLE 651 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 514
TABLE 652 NATERA, INC.: COMPANY OVERVIEW 515
TABLE 653 NATERA, INC.: PRODUCTS OFFERED 516
TABLE 654 NATERA, INC.: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026 517
TABLE 655 NATERA, INC.: DEALS JANUARY 2023–AUGUST 2026 518
TABLE 656 NATERA, INC: EXPANSIONS, JANUARY 2023–AUGUST 2026 518
TABLE 657 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 519
TABLE 658 NEOGENOMICS LABORATORIES, INC: COMPANY OVERVIEW 520
TABLE 659 NEOGENOMICS LABORATORIES, INC: PRODUCTS OFFERED 521
TABLE 660 NEOGENOMICS LABORATORIES, INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–AUGUST 2026 521
TABLE 661 NEOGENOMICS LABORATORIES, INC: DEALS, JANUARY 2023–AUGUST 2026 522
TABLE 662 NEOGENOMICS LABORATORIES, INC: EXPANSIONS, JANUARY 2023–AUGUST 2026 522
TABLE 663 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 523
TABLE 664 MYRIAD GENETICS, INC.: PRODUCTS OFFERED 524
TABLE 665 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 525
TABLE 666 MYRIAD GENETICS, INC.: DEALS, JANUARY 2023–AUGUST 2026 526
TABLE 667 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 528
TABLE 668 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 529
TABLE 669 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 531
TABLE 670 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–AUGUST 2026 532
TABLE 671 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026 532
TABLE 672 QUEST DIAGNOSTICS: COMPANY OVERVIEW 533
TABLE 673 QUEST DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 534
TABLE 674 QUEST DIAGNOSTICS: PRODUCT/SERVICES LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 535
TABLE 675 QUEST DIAGNOSTICS: DEALS, JANUARY 2023–AUGUST 2026 535
TABLE 676 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW 537
TABLE 677 CARIS LIFE SCIENCES, INC.: PRODUCTS OFFERED 538
TABLE 678 CARIS LIFE SCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–AUGUST 2026 539
TABLE 679 CARIS LIFE SCIENCES, INC.: DEALS, JANUARY 2023–AUGUST 2026 540
TABLE 680 DANAHER: COMPANY OVERVIEW 541
TABLE 681 DANAHER: PRODUCTS OFFERED 543
TABLE 682 DANAHER: DEALS, JANUARY 2023–AUGUST 2026 544
TABLE 683 KEY DATA FROM PRIMARY SOURCES 558
TABLE 684 STUDY ASSUMPTIONS 566
TABLE 685 CANCER/TUMOR PROFILING MARKET: RISK ASSESSMENT 568
FIGURE 1 CANCER/TUMOR PROFILING MARKET SEGMENTATION & REGIONAL SCOPE 50
FIGURE 2 STUDY YEARS CONSIDERED 52
FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 54
FIGURE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, 2024–2031 54
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025 55
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF
CANCER/TUMOR PROFILING MARKET 56
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN
CANCER/TUMOR PROFILING MARKET, 2025 57
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 58
FIGURE 9 INCREASING ADOPTION OF PRECISION ONCOLOGY TO DRIVE MARKET 59
FIGURE 10 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 59
FIGURE 11 ASSAYS, KITS & REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 60
FIGURE 12 CLINICAL TUMOR PROFILING TESTING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 60
FIGURE 13 NEXT GENERATION SEQUENCING SEGMENT TO LEAD MARKET
DURING FORECAST PERIOD 61
FIGURE 14 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 61
FIGURE 15 CLINICAL APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 62
FIGURE 16 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION AND PROGNOSTIC/RISK ASSESSMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 62
FIGURE 17 BIOMARKER, TARGET AND EARLY DRUG DISCOVERY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 63
FIGURE 18 SOLID TUMOR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 63
FIGURE 19 LUNG CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 64
FIGURE 20 LEUKEMIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 64
FIGURE 21 HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 65
FIGURE 22 DEDICATED CANCER HOSPITALS AND CANCER CENTERS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 65
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 66
FIGURE 24 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
FIGURE 25 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 26 CANCER/TUMOR PROFILING MARKET: SUPPLY CHAIN ANALYSIS 84
FIGURE 27 CANCER/ TUMOR PROFILING MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 28 CANCER/TUMOR PROFILING MARKET: ECOSYSTEM ANALYSIS 88
FIGURE 29 CANCER/TUMOR PROFILING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES OF KEY PLAYERS IN THE CANCER/TUMOR PROFILING MARKET 95
FIGURE 31 PATENT ANALYSIS FOR CANCER/TUMOR PROFILING MARKET,
JANUARY 2016–DECEMBER 2025 103
FIGURE 32 MARKET POTENTIAL OF AI IN CANCER/TUMOR PROFILING MARKET 105
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE OFFERING 119
FIGURE 34 KEY BUYING CRITERIA, BY PRODUCT & SERVICE OFFERING 120
FIGURE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT 269
FIGURE 36 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT 341
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025 (USD MILLION) 445
FIGURE 38 CANCER/TUMOR PROFILING MARKET SHARE ANALYSIS, 2025 (GLOBAL) 446
FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 448
FIGURE 40 CANCER/TUMOR PROFILING MARKET: COMPANY FOOTPRINT 449
FIGURE 41 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 454
FIGURE 42 EV/EBITDA OF KEY VENDORS 456
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 457
FIGURE 44 CANCER/TUMOR PROFILING MARKET: BRAND/PRODUCT COMPARISON FOR CANCER/TUMOR PROFILING 458
FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 478
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 484
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 489
FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2025) 493
FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2025) 499
FIGURE 50 LABCORP: COMPANY SNAPSHOT (2025) 505
FIGURE 51 ABBOTT: COMPANY SNAPSHOT (2025) 509
FIGURE 52 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025) 512
FIGURE 53 NATERA, INC.: COMPANY SNAPSHOT (2025) 516
FIGURE 54 NEOGENOMICS LABORATORIES, INC: COMPANY SNAPSHOT (2025) 520
FIGURE 55 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025) 524
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 529
FIGURE 57 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025) 534
FIGURE 58 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025) 538
FIGURE 59 DANAHER: COMPANY SNAPSHOT (2025) 542
FIGURE 60 RESEARCH DESIGN 555
FIGURE 61 KEY DATA FROM SECONDARY SOURCES 557
FIGURE 62 LIST OF PRIMARY SOURCES 558
FIGURE 63 KEY INDUSTRY INSIGHTS 560
FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE,
DESIGNATION, AND REGION 560
FIGURE 65 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 561
FIGURE 66 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031): IMPACT ON MARKET GROWTH AND CAGR 563
FIGURE 67 CAGR PROJECTIONS 563
FIGURE 68 TOP-DOWN APPROACH 564
FIGURE 69 DATA TRIANGULATION 565
FIGURE 70 PARAMETRIC ASSUMPTIONS 567
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們